CD8A and gastric cancer: A recent report from a Phase I clinical trial of gastric cancer patients also documented a reversal of dysfunction in vaccine‐induced CD8+ T cells when these cells were re‐stimulated in the presence of blocking antibodies against various checkpoint receptors, suggesting that a combination of DC vaccination and checkpoint blockade could also have therapeutic benefit in patients.342